hiv-infections

Documents about hiv-infections

• Determination of HIV-1 Production by the Prostate#851893ClinicalTrials.gov
• Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women#852409ClinicalTrials.gov
• Safety and Tolerability of Z-100 in Patients With Early HIV Infection#873644ClinicalTrials.gov
• Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED)#883852ClinicalTrials.gov
• A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine#350013ClinicalTrials.gov
• "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"#801900ClinicalTrials.gov
• Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations#836125ClinicalTrials.gov
• Safety of and Immune Response to an HIV DNA Plasmid Vaccine Followed by HIV Adenoviral Vector Vaccine in Healthy African Adults#864982ClinicalTrials.gov
• Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection#893915ClinicalTrials.gov
• The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients#903227ClinicalTrials.gov
• Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women#827312ClinicalTrials.gov
• A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects#855639ClinicalTrials.gov
• An Effective Alternative to the Standard Referral System for HIV Testing in the Emergency Department During Off Hour Tours: A Randomized Trial#857746ClinicalTrials.gov
• Development and Evaluation of an HIV, STD, and Pregnancy Prevention Program for Middle School Students#829612ClinicalTrials.gov
• Integration of HIV Care and Treatment Into Antenatal Care in Migori District, Kenya#847185ClinicalTrials.gov
• A Study to Compare Two Different Anti-HIV Drug Regimens#854656ClinicalTrials.gov
• A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies#856678ClinicalTrials.gov
• Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART#882726ClinicalTrials.gov
• An Open-label Trial of the Effect of Valacyclovir on Plasma HIV-1 Levels Among HIV-1 Seropositive and HSV-1/2 Seronegative Persons#887700ClinicalTrials.gov
• Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro#172352ClinicalTrials.gov
• Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults#184912ClinicalTrials.gov
• Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults#208290ClinicalTrials.gov
• A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers#454058ClinicalTrials.gov
• The Effects of a Supervised Exercise Program on Self Efficacy of People Living With HIV/AIDS.#805651ClinicalTrials.gov
• Effect of Atazanavir on Endothelial Function in HIV-Infected Patients#841259ClinicalTrials.gov
• A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy#897454ClinicalTrials.gov
• Hepatitis B and HIV Co-Infection in Patients in Uganda#901476ClinicalTrials.gov
• Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients#813103ClinicalTrials.gov
• Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults#831554ClinicalTrials.gov
• HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV : annex 16 : implementation plan#381553WHO IRIS
• Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis#888605ClinicalTrials.gov
• Same-Day Antiretroviral Therapy Initiation#804011ClinicalTrials.gov
• Leaving Nobody Out#884199ClinicalTrials.gov
• Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa#148569ClinicalTrials.gov
• Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus#405217ClinicalTrials.gov
• Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS#907362ClinicalTrials.gov
• Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women#154715ClinicalTrials.gov
• Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection#838791ClinicalTrials.gov
• Syphilis and HIV Point of Care Testing (POCT) in Saskatchewan#845197ClinicalTrials.gov
• Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities#852677ClinicalTrials.gov
• Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM#860230ClinicalTrials.gov
• Developing Interventions for Protecting HIV-Exposed Uninfected Infants Against Severe Infections#860247ClinicalTrials.gov
• SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC#866891ClinicalTrials.gov
• Effect Of Maraviroc On The Pharmacokinetics Of Digoxin#872416ClinicalTrials.gov
• Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV Medication Adherence#876965ClinicalTrials.gov
• A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.#881344ClinicalTrials.gov
• Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy#901240ClinicalTrials.gov
• The Effect of Anti-HIV Therapy on Fat Metabolism in HIV-Positive Patients#898316ClinicalTrials.gov
• A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects#162531ClinicalTrials.gov
• Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)#307319ClinicalTrials.gov